Date: Thursday 9th November 2023
Time: 11:00-12:00 EST | 16:00-17:00 GMT | 17:00-18:00 CET
Speakers: Kristian Brock and Peter Thall
Chair: Sebastian Weber
Who is this event intended for? Anyone interested in learning more about Bayesian approaches in safety and efficacy.
What is the benefit of attending? People should attend to learn more about the different techniques and application of Bayesian methods for efficacy and safety endpoints.
Please join us to hear Kristian Brock and Peter Thall present their recent work.
Presenters & Papers:
1. Kristian Brock, Chen Chen, Shuyen Ho, Greg Fuller, Jared Woolfolk, Cindy McShea, Nils Penard: 'A Bayesian method for safety signal detection in ongoing blinded randomised controlled trials'
https://onlinelibrary.wiley.com/doi/10.1002/pst.2278
2. Yun Qing, Peter F. Thall, Ying Yuan: 'A Bayesian piecewise exponential phase II design for monitoring a time-to-event endpoint'
https://onlinelibrary.wiley.com/doi/10.1002/pst.2256
PSI Journal Club is sponsored by Wiley. For each of these published papers there will be a 20 minute presentation by author followed by a 10 minute discussion.
Papers are available to view prior to the meeting (see above) and presentation slides will be available a week before the JC. Journal subscribers can access papers at any time. Audio recordings will be available shortly after the JC to download from the PSI website.
|
Speaker |
Biography |
|
|
Peter Thall is a Professor in the Department of Biostatistics at M.D. Anderson Cancer Center. He is a Fellow of the American Statistical Association and the Society for Clinical Trials, and received the Don Owen Award in 2014. Dr. Thall has over 300 publications in the statistical and medical literature, including the books Bayesian Designs for Phase I-II Clinical Trials (2016) and Statistical Remedies for Medical Researchers (2020). His research areas include Bayesian statistics, clinical trial design, precision medicine, and dynamic treatment regimes. |
|
|
Kristian is a methodologist statistician interested in Bayesian and computational methods currently working in AstraZeneca’s Statistical Innovation team. He started his biostatistical career in 2014 at the Cancer Research UK Clinical Trials Unit at the University of Birmingham, focusing mostly on phase I and II trials in cancer. Whilst at Birmingham, he obtained a PhD in clinical trial methodology, publishing work on seamless phase I/II dose-finding, and incorporating a predictive biomarker in a phase II trial with co-primary efficacy and toxicity outcomes. In 2020, he joined UCB as a methodologist. There he built tools to calculate trial probability of success, and published a Bayesian method for monitoring safety signals in ongoing blinded studies using a meta-analytic predictive prior. He is a keen programmer, with a particular interest in R, Stan, Julia, Turing. He has published CRAN packages on dose-finding methods. Outside of work, Kristian enjoys travelling, cycling and sailing. |
|
Chair |
|
|
|
Sebastian Weber is working as Director in the Department of Advanced Methodology and Data Science at Novartis. He has worked extensivley on enabling the use of historical (control) information in clinical trials through consulting and working on tools to facilitate the application of historical control information from trial design to analysis. Furthermore, Sebastian has experience in designing Oncology phase I dose-escalation trails and is also involved in pediatric drug development programs, where he applies extrapolation concepts. His research interests include the application of pharmacometrics in statistics, model-based drug development and application of Bayesian methods for drug development. |
Date: Thursday 9th November 2023
Time: 11:00-12:00 EST | 16:00-17:00 GMT | 17:00-18:00 CET
Speakers: Kristian Brock and Peter Thall
Chair: Sebastian Weber
Who is this event intended for? Anyone interested in learning more about Bayesian approaches in safety and efficacy.
What is the benefit of attending? People should attend to learn more about the different techniques and application of Bayesian methods for efficacy and safety endpoints.
Please join us to hear Kristian Brock and Peter Thall present their recent work.
Presenters & Papers:
1. Kristian Brock, Chen Chen, Shuyen Ho, Greg Fuller, Jared Woolfolk, Cindy McShea, Nils Penard: 'A Bayesian method for safety signal detection in ongoing blinded randomised controlled trials'
https://onlinelibrary.wiley.com/doi/10.1002/pst.2278
2. Yun Qing, Peter F. Thall, Ying Yuan: 'A Bayesian piecewise exponential phase II design for monitoring a time-to-event endpoint'
https://onlinelibrary.wiley.com/doi/10.1002/pst.2256
PSI Journal Club is sponsored by Wiley. For each of these published papers there will be a 20 minute presentation by author followed by a 10 minute discussion.
Papers are available to view prior to the meeting (see above) and presentation slides will be available a week before the JC. Journal subscribers can access papers at any time. Audio recordings will be available shortly after the JC to download from the PSI website.
|
Speaker |
Biography |
|
|
Peter Thall is a Professor in the Department of Biostatistics at M.D. Anderson Cancer Center. He is a Fellow of the American Statistical Association and the Society for Clinical Trials, and received the Don Owen Award in 2014. Dr. Thall has over 300 publications in the statistical and medical literature, including the books Bayesian Designs for Phase I-II Clinical Trials (2016) and Statistical Remedies for Medical Researchers (2020). His research areas include Bayesian statistics, clinical trial design, precision medicine, and dynamic treatment regimes. |
|
|
Kristian is a methodologist statistician interested in Bayesian and computational methods currently working in AstraZeneca’s Statistical Innovation team. He started his biostatistical career in 2014 at the Cancer Research UK Clinical Trials Unit at the University of Birmingham, focusing mostly on phase I and II trials in cancer. Whilst at Birmingham, he obtained a PhD in clinical trial methodology, publishing work on seamless phase I/II dose-finding, and incorporating a predictive biomarker in a phase II trial with co-primary efficacy and toxicity outcomes. In 2020, he joined UCB as a methodologist. There he built tools to calculate trial probability of success, and published a Bayesian method for monitoring safety signals in ongoing blinded studies using a meta-analytic predictive prior. He is a keen programmer, with a particular interest in R, Stan, Julia, Turing. He has published CRAN packages on dose-finding methods. Outside of work, Kristian enjoys travelling, cycling and sailing. |
|
Chair |
|
|
|
Sebastian Weber is working as Director in the Department of Advanced Methodology and Data Science at Novartis. He has worked extensivley on enabling the use of historical (control) information in clinical trials through consulting and working on tools to facilitate the application of historical control information from trial design to analysis. Furthermore, Sebastian has experience in designing Oncology phase I dose-escalation trails and is also involved in pediatric drug development programs, where he applies extrapolation concepts. His research interests include the application of pharmacometrics in statistics, model-based drug development and application of Bayesian methods for drug development. |
Date: Thursday 9th November 2023
Time: 11:00-12:00 EST | 16:00-17:00 GMT | 17:00-18:00 CET
Speakers: Kristian Brock and Peter Thall
Chair: Sebastian Weber
Who is this event intended for? Anyone interested in learning more about Bayesian approaches in safety and efficacy.
What is the benefit of attending? People should attend to learn more about the different techniques and application of Bayesian methods for efficacy and safety endpoints.
Please join us to hear Kristian Brock and Peter Thall present their recent work.
Presenters & Papers:
1. Kristian Brock, Chen Chen, Shuyen Ho, Greg Fuller, Jared Woolfolk, Cindy McShea, Nils Penard: 'A Bayesian method for safety signal detection in ongoing blinded randomised controlled trials'
https://onlinelibrary.wiley.com/doi/10.1002/pst.2278
2. Yun Qing, Peter F. Thall, Ying Yuan: 'A Bayesian piecewise exponential phase II design for monitoring a time-to-event endpoint'
https://onlinelibrary.wiley.com/doi/10.1002/pst.2256
PSI Journal Club is sponsored by Wiley. For each of these published papers there will be a 20 minute presentation by author followed by a 10 minute discussion.
Papers are available to view prior to the meeting (see above) and presentation slides will be available a week before the JC. Journal subscribers can access papers at any time. Audio recordings will be available shortly after the JC to download from the PSI website.
|
Speaker |
Biography |
|
|
Peter Thall is a Professor in the Department of Biostatistics at M.D. Anderson Cancer Center. He is a Fellow of the American Statistical Association and the Society for Clinical Trials, and received the Don Owen Award in 2014. Dr. Thall has over 300 publications in the statistical and medical literature, including the books Bayesian Designs for Phase I-II Clinical Trials (2016) and Statistical Remedies for Medical Researchers (2020). His research areas include Bayesian statistics, clinical trial design, precision medicine, and dynamic treatment regimes. |
|
|
Kristian is a methodologist statistician interested in Bayesian and computational methods currently working in AstraZeneca’s Statistical Innovation team. He started his biostatistical career in 2014 at the Cancer Research UK Clinical Trials Unit at the University of Birmingham, focusing mostly on phase I and II trials in cancer. Whilst at Birmingham, he obtained a PhD in clinical trial methodology, publishing work on seamless phase I/II dose-finding, and incorporating a predictive biomarker in a phase II trial with co-primary efficacy and toxicity outcomes. In 2020, he joined UCB as a methodologist. There he built tools to calculate trial probability of success, and published a Bayesian method for monitoring safety signals in ongoing blinded studies using a meta-analytic predictive prior. He is a keen programmer, with a particular interest in R, Stan, Julia, Turing. He has published CRAN packages on dose-finding methods. Outside of work, Kristian enjoys travelling, cycling and sailing. |
|
Chair |
|
|
|
Sebastian Weber is working as Director in the Department of Advanced Methodology and Data Science at Novartis. He has worked extensivley on enabling the use of historical (control) information in clinical trials through consulting and working on tools to facilitate the application of historical control information from trial design to analysis. Furthermore, Sebastian has experience in designing Oncology phase I dose-escalation trails and is also involved in pediatric drug development programs, where he applies extrapolation concepts. His research interests include the application of pharmacometrics in statistics, model-based drug development and application of Bayesian methods for drug development. |
Date: Thursday 9th November 2023
Time: 11:00-12:00 EST | 16:00-17:00 GMT | 17:00-18:00 CET
Speakers: Kristian Brock and Peter Thall
Chair: Sebastian Weber
Who is this event intended for? Anyone interested in learning more about Bayesian approaches in safety and efficacy.
What is the benefit of attending? People should attend to learn more about the different techniques and application of Bayesian methods for efficacy and safety endpoints.
Please join us to hear Kristian Brock and Peter Thall present their recent work.
Presenters & Papers:
1. Kristian Brock, Chen Chen, Shuyen Ho, Greg Fuller, Jared Woolfolk, Cindy McShea, Nils Penard: 'A Bayesian method for safety signal detection in ongoing blinded randomised controlled trials'
https://onlinelibrary.wiley.com/doi/10.1002/pst.2278
2. Yun Qing, Peter F. Thall, Ying Yuan: 'A Bayesian piecewise exponential phase II design for monitoring a time-to-event endpoint'
https://onlinelibrary.wiley.com/doi/10.1002/pst.2256
PSI Journal Club is sponsored by Wiley. For each of these published papers there will be a 20 minute presentation by author followed by a 10 minute discussion.
Papers are available to view prior to the meeting (see above) and presentation slides will be available a week before the JC. Journal subscribers can access papers at any time. Audio recordings will be available shortly after the JC to download from the PSI website.
|
Speaker |
Biography |
|
|
Peter Thall is a Professor in the Department of Biostatistics at M.D. Anderson Cancer Center. He is a Fellow of the American Statistical Association and the Society for Clinical Trials, and received the Don Owen Award in 2014. Dr. Thall has over 300 publications in the statistical and medical literature, including the books Bayesian Designs for Phase I-II Clinical Trials (2016) and Statistical Remedies for Medical Researchers (2020). His research areas include Bayesian statistics, clinical trial design, precision medicine, and dynamic treatment regimes. |
|
|
Kristian is a methodologist statistician interested in Bayesian and computational methods currently working in AstraZeneca’s Statistical Innovation team. He started his biostatistical career in 2014 at the Cancer Research UK Clinical Trials Unit at the University of Birmingham, focusing mostly on phase I and II trials in cancer. Whilst at Birmingham, he obtained a PhD in clinical trial methodology, publishing work on seamless phase I/II dose-finding, and incorporating a predictive biomarker in a phase II trial with co-primary efficacy and toxicity outcomes. In 2020, he joined UCB as a methodologist. There he built tools to calculate trial probability of success, and published a Bayesian method for monitoring safety signals in ongoing blinded studies using a meta-analytic predictive prior. He is a keen programmer, with a particular interest in R, Stan, Julia, Turing. He has published CRAN packages on dose-finding methods. Outside of work, Kristian enjoys travelling, cycling and sailing. |
|
Chair |
|
|
|
Sebastian Weber is working as Director in the Department of Advanced Methodology and Data Science at Novartis. He has worked extensivley on enabling the use of historical (control) information in clinical trials through consulting and working on tools to facilitate the application of historical control information from trial design to analysis. Furthermore, Sebastian has experience in designing Oncology phase I dose-escalation trails and is also involved in pediatric drug development programs, where he applies extrapolation concepts. His research interests include the application of pharmacometrics in statistics, model-based drug development and application of Bayesian methods for drug development. |
Date: Thursday 9th November 2023
Time: 11:00-12:00 EST | 16:00-17:00 GMT | 17:00-18:00 CET
Speakers: Kristian Brock and Peter Thall
Chair: Sebastian Weber
Who is this event intended for? Anyone interested in learning more about Bayesian approaches in safety and efficacy.
What is the benefit of attending? People should attend to learn more about the different techniques and application of Bayesian methods for efficacy and safety endpoints.
Please join us to hear Kristian Brock and Peter Thall present their recent work.
Presenters & Papers:
1. Kristian Brock, Chen Chen, Shuyen Ho, Greg Fuller, Jared Woolfolk, Cindy McShea, Nils Penard: 'A Bayesian method for safety signal detection in ongoing blinded randomised controlled trials'
https://onlinelibrary.wiley.com/doi/10.1002/pst.2278
2. Yun Qing, Peter F. Thall, Ying Yuan: 'A Bayesian piecewise exponential phase II design for monitoring a time-to-event endpoint'
https://onlinelibrary.wiley.com/doi/10.1002/pst.2256
PSI Journal Club is sponsored by Wiley. For each of these published papers there will be a 20 minute presentation by author followed by a 10 minute discussion.
Papers are available to view prior to the meeting (see above) and presentation slides will be available a week before the JC. Journal subscribers can access papers at any time. Audio recordings will be available shortly after the JC to download from the PSI website.
|
Speaker |
Biography |
|
|
Peter Thall is a Professor in the Department of Biostatistics at M.D. Anderson Cancer Center. He is a Fellow of the American Statistical Association and the Society for Clinical Trials, and received the Don Owen Award in 2014. Dr. Thall has over 300 publications in the statistical and medical literature, including the books Bayesian Designs for Phase I-II Clinical Trials (2016) and Statistical Remedies for Medical Researchers (2020). His research areas include Bayesian statistics, clinical trial design, precision medicine, and dynamic treatment regimes. |
|
|
Kristian is a methodologist statistician interested in Bayesian and computational methods currently working in AstraZeneca’s Statistical Innovation team. He started his biostatistical career in 2014 at the Cancer Research UK Clinical Trials Unit at the University of Birmingham, focusing mostly on phase I and II trials in cancer. Whilst at Birmingham, he obtained a PhD in clinical trial methodology, publishing work on seamless phase I/II dose-finding, and incorporating a predictive biomarker in a phase II trial with co-primary efficacy and toxicity outcomes. In 2020, he joined UCB as a methodologist. There he built tools to calculate trial probability of success, and published a Bayesian method for monitoring safety signals in ongoing blinded studies using a meta-analytic predictive prior. He is a keen programmer, with a particular interest in R, Stan, Julia, Turing. He has published CRAN packages on dose-finding methods. Outside of work, Kristian enjoys travelling, cycling and sailing. |
|
Chair |
|
|
|
Sebastian Weber is working as Director in the Department of Advanced Methodology and Data Science at Novartis. He has worked extensivley on enabling the use of historical (control) information in clinical trials through consulting and working on tools to facilitate the application of historical control information from trial design to analysis. Furthermore, Sebastian has experience in designing Oncology phase I dose-escalation trails and is also involved in pediatric drug development programs, where he applies extrapolation concepts. His research interests include the application of pharmacometrics in statistics, model-based drug development and application of Bayesian methods for drug development. |
Date: Thursday 9th November 2023
Time: 11:00-12:00 EST | 16:00-17:00 GMT | 17:00-18:00 CET
Speakers: Kristian Brock and Peter Thall
Chair: Sebastian Weber
Who is this event intended for? Anyone interested in learning more about Bayesian approaches in safety and efficacy.
What is the benefit of attending? People should attend to learn more about the different techniques and application of Bayesian methods for efficacy and safety endpoints.
Please join us to hear Kristian Brock and Peter Thall present their recent work.
Presenters & Papers:
1. Kristian Brock, Chen Chen, Shuyen Ho, Greg Fuller, Jared Woolfolk, Cindy McShea, Nils Penard: 'A Bayesian method for safety signal detection in ongoing blinded randomised controlled trials'
https://onlinelibrary.wiley.com/doi/10.1002/pst.2278
2. Yun Qing, Peter F. Thall, Ying Yuan: 'A Bayesian piecewise exponential phase II design for monitoring a time-to-event endpoint'
https://onlinelibrary.wiley.com/doi/10.1002/pst.2256
PSI Journal Club is sponsored by Wiley. For each of these published papers there will be a 20 minute presentation by author followed by a 10 minute discussion.
Papers are available to view prior to the meeting (see above) and presentation slides will be available a week before the JC. Journal subscribers can access papers at any time. Audio recordings will be available shortly after the JC to download from the PSI website.
|
Speaker |
Biography |
|
|
Peter Thall is a Professor in the Department of Biostatistics at M.D. Anderson Cancer Center. He is a Fellow of the American Statistical Association and the Society for Clinical Trials, and received the Don Owen Award in 2014. Dr. Thall has over 300 publications in the statistical and medical literature, including the books Bayesian Designs for Phase I-II Clinical Trials (2016) and Statistical Remedies for Medical Researchers (2020). His research areas include Bayesian statistics, clinical trial design, precision medicine, and dynamic treatment regimes. |
|
|
Kristian is a methodologist statistician interested in Bayesian and computational methods currently working in AstraZeneca’s Statistical Innovation team. He started his biostatistical career in 2014 at the Cancer Research UK Clinical Trials Unit at the University of Birmingham, focusing mostly on phase I and II trials in cancer. Whilst at Birmingham, he obtained a PhD in clinical trial methodology, publishing work on seamless phase I/II dose-finding, and incorporating a predictive biomarker in a phase II trial with co-primary efficacy and toxicity outcomes. In 2020, he joined UCB as a methodologist. There he built tools to calculate trial probability of success, and published a Bayesian method for monitoring safety signals in ongoing blinded studies using a meta-analytic predictive prior. He is a keen programmer, with a particular interest in R, Stan, Julia, Turing. He has published CRAN packages on dose-finding methods. Outside of work, Kristian enjoys travelling, cycling and sailing. |
|
Chair |
|
|
|
Sebastian Weber is working as Director in the Department of Advanced Methodology and Data Science at Novartis. He has worked extensivley on enabling the use of historical (control) information in clinical trials through consulting and working on tools to facilitate the application of historical control information from trial design to analysis. Furthermore, Sebastian has experience in designing Oncology phase I dose-escalation trails and is also involved in pediatric drug development programs, where he applies extrapolation concepts. His research interests include the application of pharmacometrics in statistics, model-based drug development and application of Bayesian methods for drug development. |
Our monthly webinar explores examples of innovative data visualisations relevant to our day to day work. Each month a new dataset is provided from a clinical trial or other relevant example, and participants are invited to submit a graphic that communicates interesting and relevant characteristics of the data.
Our monthly webinar will allow attendees to gain practical knowledge and skills in Open-Source coding and tools, with a focus on applications in the pharmaceutical industry. The sessions will provide starting points in a number of areas, correct any common misconceptions and provide valuable resources for further learning.
Develop your non-technical skills by reading The Art of Explanation by Ros Atkins and joining the Sept-Dec 2025 book club. You will be invited to join facilitated discussions of the concepts and ideas and apply skills from the book in-between sessions.
Date: Tuesday 9th September 2025 Join us to hear Sofia Weigle and Weng-Kee Wong present their recent work.
This course is aimed at biostatisticians with no or some pediatric drug development experience who are interested to further their understanding. We will give you an introduction to the pediatric drug development landscape. This will include identifying the key regulations and processes governing pediatric development, a discussion on the needs and challenges when conducting pediatric research and a focus on the ways to overcome these challenges from a statistical perspective.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
AI agents are large language models equipped with tools that can autonomously tackle challenging tasks. This talk will explore how generative AI agents can enable biomedical discovery.
The webinar is targeted at statisticians working in the pharmaceutical industry, and the objective is to 1) provide a basic understanding of IV methodology including how it relates to causal inference, and 2) present two inspirational pharma-relevant applications.
The Pre-Clinical Special Interest Group (SIG) Workshop 2025 will take place over two half-days on 7 - 8 October in Verona, Italy, bringing together experts from industry, academia, and regulatory institutions to discuss key challenges and innovations in pre-clinical research.
Four sessions will include ML foundation (including an introduction, data exploration for ML and dimensionality reduction and feature selection), Supervised learning (including support vector machines and model evaluation and interpretation), model optimization and unsupervised learning (including clustering) and advanced topics (including neural networks, deep learning and large language models).
The program will feature insightful sessions led by distinguished invited speakers, alongside a poster session showcasing the latest advancements in the field. Further details will be provided.
Date: Wednesday 5th November 2025 A careers talk about medical statistics and how it plays a crucial role in developing new medicines
Date: 19 November 2025 This event is aimed at students with an interest in the field of Medical Statistics, for example within pharmaceuticals, healthcare and/or medical research.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
As an Associate Director Biostatistics Early Development, you will be a key member of our biostatistics group, you will play a crucial role in the design, analysis, and interpretation of clinical trials for early development programs.
If you are passionate about biostatistics and real-world data, and are looking for an exciting opportunity to contribute to groundbreaking research, we encourage you to apply.
Are you passionate about making a difference in the world of healthcare? Novartis is seeking a dynamic and experienced professional to join our team in London at The Westworks.
As the Director of HTA Biostatistics & Medical Affairs, you will play a pivotal role in shaping the future of healthcare by providing strategic biostatistical leadership and expertise.
An exciting opportunity has arisen for a permanent Senior Medical Statistician & Statistical Programmer to join the UKCRC fully registered Derby Clinical Trials Support Unit (Derby CTSU).
As a Senior Principal Biostatistician, you will be responsible and accountable for all statistical work, both scientific and operational, for one or more assigned clinical trials
About cookies on this site
We use cookies to collect and analyse information on site performance and usage, to provide social media features and to enhance and customise content and advertisements.
About cookies on this site
Cookies used on the site are categorized and below you can read about each category and allow or deny some or all of them. When categories than have been previously allowed are disabled, all cookies assigned to that category will be removed from your browser. Additionally you can see a list of cookies assigned to each category and detailed information in the cookie declaration.
Necessary cookies
Some cookies are required to provide core functionality. The website won't function properly without these cookies and they are enabled by default and cannot be disabled.
CookieHub is a Consent Management Platform (CMP) which allows users to control storage and processing of personal information.
Cloudflare is a global network designed to make everything you connect to the Internet secure, private, fast, and reliable.
Amazon Web Services offers a broad set of global cloud-based products including compute, storage, databases, analytics, networking, mobile, developer tools, management tools, IoT, security, and enterprise applications.
Microsoft Azure is a cloud computing platform offering a wide range of services, including virtual machines, databases, and AI tools.
Preferences
Preference cookies enables the web site to remember information to customize how the web site looks or behaves for each user. This may include storing selected currency, region, language or color theme.
Analytical cookies
Analytical cookies help us improve our website by collecting and reporting information on its usage.
Google Analytics is a web analytics service offered by Google that tracks and reports website traffic.
Vimeo, Inc. is an American video hosting, sharing, services provider, and broadcaster. Vimeo focuses on the delivery of high-definition video across a range of devices.
Cookies used on the site are categorized and below you can read about each category and allow or deny some or all of them. When categories than have been previously allowed are disabled, all cookies assigned to that category will be removed from your browser. Additionally you can see a list of cookies assigned to each category and detailed information in the cookie declaration.
Necessary cookies
Some cookies are required to provide core functionality. The website won't function properly without these cookies and they are enabled by default and cannot be disabled.
| Name | Hostname | Vendor | Expiry |
|---|---|---|---|
| ARRAffinity | .psiweb.org | Session | |
This cookie is set by websites run on the Windows Azure cloud platform. It is used for load balancing to make sure the visitor page requests are routed to the same server in any browsing session. | |||
| ARRAffinitySameSite | .psiweb.org | Session | |
Used to distribute traffic to the website on several servers in order to optimize response times. | |||
| __cf_bm | .vimeo.com | Cloudflare, Inc. | 1 hour |
The __cf_bm cookie supports Cloudflare Bot Management by managing incoming traffic that matches criteria associated with bots. The cookie does not collect any personal data, and any information collected is subject to one-way encryption. | |||
| _cfuvid | .vimeo.com | Session | |
Used by Cloudflare WAF to distinguish individual users who share the same IP address and apply rate limits | |||
| __cf_bm | .glueup.com | Cloudflare, Inc. | 1 hour |
The __cf_bm cookie supports Cloudflare Bot Management by managing incoming traffic that matches criteria associated with bots. The cookie does not collect any personal data, and any information collected is subject to one-way encryption. | |||
| AWSALBTGCORS | psi.glueup.com | 7 days | |
AWS Classic Load Balancer Cookie: Load Balancing Cookie: Used to map the session to the instance. Same value as AWSELB. | |||
| PHPSESSID | psi.glueup.com | Session | |
Cookie generated by applications based on the PHP language. This is a general purpose identifier used to maintain user session variables. It is normally a random generated number, how it is used can be specific to the site, but a good example is maintaining a logged-in status for a user between pages. | |||
| History.store | Session | ||
| cookiehub | .psiweb.org | CookieHub | 365 days |
Used by CookieHub to store information about whether visitors have given or declined the use of cookie categories used on the site. | |||
Preferences
Preference cookies enables the web site to remember information to customize how the web site looks or behaves for each user. This may include storing selected currency, region, language or color theme.
| Name | Hostname | Vendor | Expiry |
|---|---|---|---|
| vuid | .vimeo.com | 400 days | |
These cookies are used by the Vimeo video player on websites. | |||
| AWSALBCORS | psi.glueup.com | 7 days | |
Amazon Web Services cookie. This cookie enables us to allocate server traffic to make the user experience as smooth as possible. A so-called load balancer is used to determine which server currently has the best availability. The information generated cannot identify you as an individual. | |||
Analytical cookies
Analytical cookies help us improve our website by collecting and reporting information on its usage.
| Name | Hostname | Vendor | Expiry |
|---|---|---|---|
| _ga_ | .psiweb.org | 400 days | |
Contains a unique identifier used by Google Analytics 4 to determine that two distinct hits belong to the same user across browsing sessions. | |||
| _ga | .psiweb.org | 400 days | |
Contains a unique identifier used by Google Analytics to determine that two distinct hits belong to the same user across browsing sessions. | |||
